Publications by authors named "L A Soisson"
The highly conserved and essential Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) has emerged as the leading target for vaccines against the disease-causing blood stage of malaria. However, the features of the human vaccine-induced antibody response that confer highly potent inhibition of malaria parasite invasion into red blood cells are not well defined. Here, we characterize 236 human IgG monoclonal antibodies, derived from 15 donors, induced by the most advanced PfRH5 vaccine.
View Article and Find Full Text PDFPlasmodium falciparum reticulocyte-binding protein homolog 5 (RH5) is a leading blood-stage malaria vaccine antigen target, currently in a phase 2b clinical trial as a full-length soluble protein/adjuvant vaccine candidate called RH5.1/Matrix-M. We identify that disordered regions of the full-length RH5 molecule induce non-growth inhibitory antibodies in human vaccinees and that a re-engineered and stabilized immunogen (including just the alpha-helical core of RH5) induces a qualitatively superior growth inhibitory antibody response in rats vaccinated with this protein formulated in Matrix-M adjuvant.
View Article and Find Full Text PDFReticulocyte-binding protein homologue 5 (RH5), a leading blood-stage Plasmodium falciparum malaria vaccine target, interacts with cysteine-rich protective antigen (CyRPA) and RH5-interacting protein (RIPR) to form an essential heterotrimeric "RCR-complex". We investigate whether RCR-complex vaccination can improve upon RH5 alone. Using monoclonal antibodies (mAbs) we show that parasite growth-inhibitory epitopes on each antigen are surface-exposed on the RCR-complex and that mAb pairs targeting different antigens can function additively or synergistically.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess the safety, immune response, and effectiveness of the malaria vaccine RTS,S/AS02 when combined with another protein (FMP1) in healthy adults.
- Sixty participants were divided into four groups to receive different vaccine combinations, and results indicated that co-administering RTS,S and FMP1 at the same site decreased RTS,S antibody levels but maintained similar levels of safety and cellular immune response.
- Immunized groups with RTS,S showed about 30% efficacy in preventing malaria after exposure, while the FMP1 alone group did not demonstrate any protective effect.
Article Synopsis
- RH5 is a promising vaccine candidate against Plasmodium falciparum, showing some effectiveness in reducing parasite growth during human trials, especially when combined with Ripr and CyRPA.
- Researchers tested various combinations of these proteins in mice and rats to determine the best immune response and found that the DPX® adjuvant significantly enhanced the production of protective antibodies.
- While combining RH5 with other antigens showed potential, it may not provide better immunity than using RH5 alone, suggesting that future vaccines could explore different antigen combinations.